GLPwatch
Aspiration risk under anesthesia
0 FAERS reports across 0 drugs
Last updated 2026-05-28 15:46 UTCThe chance that stomach contents or saliva could accidentally enter the lungs during a medical procedure when a person is unconscious.
Plain-language definition of the term.
FDA labels for GLP-1 drugs (e.g., Byetta, Mounjaro, Ozempic, Rybelsus, Saxenda, Soliqua, Wegovy, Xultophy, Zepbound) include warnings about aspiration risk under anesthesia in their 'Warnings and cautions' and 'Adverse reactions' sections.
AI summary of the sources below.
FAERS report counts reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
No FAERS reports for this side effect in the current sample.
Mentioned in FDA labels
Research mentioning aspiration risk under anesthesia (7)
- Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.
- Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD.
- A Scoping Review of GLP-1 Receptor Agonists: Are They Associated with Increased Gastric Contents, Regurgitation, and Aspiration Events?
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.
- Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence.
- [<sup>18</sup>F]FB(ePEG12)12-exendin-4 noninvasive imaging of insulinoma negative for insulin immunostaining on specimen from endoscopic ultrasonography-guided fine needle aspiration: a case report with review of literature.
- In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists.